journal article·2022-08

Toward understanding the kinetics of disassembly of ferritins of varying origin and subunit composition

Katerina Krausova, Marketa Charousova, Zdenek Kratochvil, Paulina Takacsova, Barbora Tesarova, Ladislav Sivak, Marie Kudlickova Peskova, Martina Sukupova, Hana Zivotska, Pavol Makovicky, Ichiro Yamashita, Naofumi Okamoto, David Hynek, Yazan Haddad, Vladimir Pekarik, Simona Rex, Zbynek Heger

Publisher page

Abstract

Understanding the reversible reassembly properties of ferritins (FRTs) is crucial for enabling their applicability in nanomedicine. These properties include drug loading capabilities and also subsequent payload release in desired site-of-action. Thus, the presented study is focused on understanding the disassembly of recombinantly produced FRTs of varying origin and subunit composition, i.e. equine FRT composed of 22 L- and 2 H-subunits (EcaLH) or 24 L-subunits (EcaL), human FRT composed of 24 H-subunits (HsaH) and archaeal Pyrococcus furiosus FRT (Pfu). Disassembly was distinctly influenced by pH and ionic strength. Except for Pfu, the disassembly kinetics in acidic pH is rapid upon reaching an innate threshold, reaching the final state within minutes. Disassembly kinetics in basic pH is slower. Pfu is partially disassembled within the entire pH range. While equine FRT disassembles into free subunits, HsaH disassembles into subunit clusters. EcaL and Pfu form large aggregates during disassembly in mildly acidic pH, although basic pH causes partial disassembly without aggregation, suggesting usability for basic pH-triggered drug loading. We show that in human serum/plasma, FRTs readily form protein corona, hampering their uptake. Interestingly, we found out that archaeal Pfu likely exhibits similar receptor affinity as mammalian FRTs. Further, in vivo toxicity and biodistribution study of a single dose of FRTs demonstrated very low toxicity of FRTs and their preferential liver/kidney bioaccumulation.
Source: expertdata · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Iron Metabolism and Disorders · Signaling Pathways in Disease · Clostridium difficile and Clostridium perfringens research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (72)

Show source-provided references
1. Taking advantage of cellular uptake of ferritin nanocages for targeted drug delivery10.1016/j.jconrel.2020.06.026 ↗
2. Structural characterization of encapsulated ferritin provides insight into iron storage in bacterial nanocompartments10.7554/eLife.18972 ↗
3. Protein dynamics and ion traffic in bacterioferritin10.1021/bi3013388 ↗
4. Characterization of serum ferritin in iron overload - possible identity to natural apoferritin10.1111/j.1365-2141.1977.tb00640.x ↗
5. Interactions of ferritin with scavenger receptor class A members10.1074/jbc.RA120.014690 ↗
6. A novel plant ferritin subunit from soybean that is related to a mechanism in iron release10.1074/jbc.M011399200 ↗
7. Ferritin cage for encapsulation and delivery of bioactive nutrients: from structure, property to applications10.1080/10408398.2016.1149690 ↗
8. Broad neutralization responses against oncogenic human papillomaviruses induced by a minor capsid L2 polytope genetically incorporated into bacterial ferritin nanoparticles10.3389/fimmu.2020.606569 ↗
9. X-ray structures of ferritins and related proteins10.1016/j.bbagen.2010.03.019 ↗
10. Ferritin protein nanocage ion channels - gating by N-terminal extensions10.1074/jbc.M111.332734 ↗
11. Solving biology's iron chemistry problem with ferritin protein nanocages10.1021/ar500469e ↗
12. Cryo-EM structures and functional characterization of homo- and heteropolymers of human ferritin variants10.1038/s41598-020-77717-4 ↗
13. A natural drug entry channel in the ferritin nanocage10.1016/j.nantod.2020.100948 ↗
14. Bacterial iron homeostasis10.1016/S0168-6445(03)00055-X ↗
15. The high-resolution X-ray crystallographic structure of the ferritin (EcFtnA) of Escherichia coli; Comparison with human H ferritin (HuHF) and the structures of the Fe3+ and Zn2+ derivatives10.1006/jmbi.2001.4475 ↗
16. Norepinephrine transporter-derived homing peptides enable rapid endocytosis of drug delivery nanovehicles into neuroblastoma cells10.1186/s12951-020-00654-x ↗
17. A novel protein-based anticancer drug encapsulating nanosphere: apoferritin-doxorubicin complex10.1166/jbn.2012.1406 ↗
18. pH-dependent structures of ferritin and apoferritin in solution: disassembly and reassembly10.1021/bm200026v ↗
19. Passive diffusion vs active pH-dependent encapsulation of tyrosine kinase inhibitors vandetanib and lenvatinib into folate-targeted ferritin delivery system10.2147/IJN.S275808 ↗
20. Surface-PASylation of ferritin to form stealth nanovehicles enhances in vivo therapeutic performance of encapsulated ellipticine
21. Folic acid-mediated re-shuttling of ferritin receptor specificity towards a selective delivery of highly cytotoxic nickel(II) coordination compounds10.1016/j.ijbiomac.2018.12.128 ↗
22. H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer10.1038/s41598-017-07617-7 ↗
23. Evidence that a salt bridge in the light chain contributes to the physical stability difference between heavy and light human ferritins10.1016/S0021-9258(19)49681-6 ↗
24. Development and validation of a simple and versatile method for the quantification of everolimus loaded in H-ferritin nanocages using UHPLC-MS/MS10.1016/j.jpba.2020.113644 ↗
25. Re-engineering the inner surface of ferritin nanocage enables dual drug payloads for synergistic tumor therapy10.7150/thno.68459 ↗
26. Ferritin nanocages for early theranostics of tumors via inflammation-enhanced active targeting10.1007/s11427-021-1976-0 ↗
27. Controlling protein nanocage assembly with hydrostatic pressure10.1021/jacs.0c07285 ↗
28. Stability of a 24-meric homopolymer: Comparative studies of assembly-defective mutants of Rhodobacter capsulatus bacterioferritin and the native protein10.1110/ps.0301903 ↗
29. The dodecameric ferritin from Listeria innocua contains a novel intersubunit iron-binding site10.1038/71236 ↗
30. Supramolecular protein polymers using mini-ferritin Dps as the building block10.1039/D0OB01702G ↗
31. Detergent-modified catalytic and enzymomimetic activity of silver and palladium nanoparticles biotemplated by Pyrococcus furiosus ferritin10.1016/j.jcis.2018.11.005 ↗
32. Cryo-EM structure of the human ferritin-transferrin receptor 1 complex10.1038/s41467-019-09098-w ↗
33. L-ferritin binding to Scara5: a new iron traffic pathway potentially implicated in retinopathy10.1371/journal.pone.0106974 ↗
34. TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis10.1084/jem.20042433 ↗
35. Ferritin nanocage: A promising and designable multi-module platform for constructing dynamic nanoassembly-based drug nanocarrier10.1016/j.addr.2021.113892 ↗
36. Magic ferritin: a novel chemotherapeutic encapsulation bullet10.1016/j.jmmm.2005.01.066 ↗
37. Fabrication of ZnSe nanoparticles in the apoferritin cavity by designing a slow chemical reaction system10.1021/ic0502426 ↗
38. RGD-modified apoferritin nanoparticles for efficient drug delivery to tumors10.1021/nn305791q ↗
39. Everolimus nanoformulation in biological nanoparticles increases drug responsiveness in resistant and low-responsive breast cancer cell lines10.3390/pharmaceutics11080384 ↗
40. High hydrostatic pressure encapsulation of doxorubicin in ferritin nanocages with enhanced efficiency10.1016/j.jbiotec.2017.05.025 ↗
41. Pressure provides new insights into protein folding, dynamics and structure10.1016/S0968-0004(01)01949-1 ↗
42. Site-directed conjugation of antibodies to apoferritin nanocarrier for targeted drug delivery to prostate cancer cells10.1021/acsami.6b04286 ↗
43. Prostate-specific membrane antigen-targeted site-directed antibody-conjugated apoferritin nanovehicle favorably influences in vivo side effects of doxorubicin10.1038/s41598-018-26772-z ↗
44. Apoferritin as an ubiquitous nanocarrier with excellent shelf life10.2147/IJN.S130267 ↗
45. Encapsulation of curcumin in recombinant human H-chain ferritin increases its water-solubility and stability10.1016/j.foodres.2014.05.054 ↗
46. Visualization of stable ferritin complexes with palladium, rhodium and iridium nanoparticles detected by their catalytic activity in native polyacrylamide gels10.1039/C7DT02818K ↗
47. Blood circulation-prolonging peptides for engineered nanoparticles identified via phage display10.1021/acs.nanolett.8b04007 ↗
48. On the mechanism of horse spleen apoferritin assembly - a sedimentation-velocity and circular-dichroism study10.1021/bi00381a007 ↗
49. Ferritin assembly revisited: a time-resolved small-angle X-ray scattering study10.1021/acs.biochem.5b01152 ↗
50. Electrostatic repulsion during ferritin assembly and Its screening by ions10.1021/acs.biochem.5b01197 ↗
51. Oxido-reduction is not the only mechanism allowing ions to traverse the ferritin protein shell10.1016/j.bbagen.2010.03.001 ↗
52. Electrostatic interactions in protein structure, folding, binding, and condensation10.1021/acs.chemrev.7b00305 ↗
53. His-mediated reversible self-assembly of ferritin nanocages through two different switches for encapsulation of cargo molecules10.1021/acsnano.0c06670 ↗
54. Characterization of the H- and L-subunit ratios of ferritins by sodium dodecyl sulfate-capillary gel electrophoresis10.1006/abio.2001.5561 ↗
55. H-ferritin-nanocaged doxorubicin nanoparticles specifically target and kill tumors with a single-dose injection10.1073/pnas.1407808111 ↗
56. Opening protein pores with chaotropes enhances Fe reduction and chelation of Fe from the ferritin biomineral10.1073/pnas.0636928100 ↗
57. Ferritin-supported palladium nanoclusters: selective catalysts for aerobic oxidations in water10.1039/c2cc31401k ↗
58. Questions about horse spleen ferritin crossing the blood brain barrier via mouse transferrin receptor 110.1007/s13238-017-0481-8 ↗
59. Human ferritin platform and its optimized structures to enhance anti-cancer immunity
60. Conserved domains of the class A scavenger receptors: evolution and function10.1111/j.1600-065X.2008.00728.x ↗
61. Identification and characterization of murine SCARA5, a novel class A scavenger receptor that is expressed by populations of epithelial cells10.1074/jbc.M507599200 ↗
62. Protein-nanoparticle interactions: what does the cell see?10.1038/nnano.2009.248 ↗
63. Understanding the kinetics of protein-nanoparticle corona formation10.1021/acsnano.6b04858 ↗
64. Regulatory effects of ferritin on angiogenesis10.1073/pnas.0812010106 ↗
65. Scara5 Is a ferritin receptor mediating non-transferrin iron delivery10.1016/j.devcel.2008.12.002 ↗
66. Serum ferritin: past, present and future10.1016/j.bbagen.2010.03.011 ↗
67. Regulated secretion of glycosylated human ferritin from hepatocytes10.1182/blood-2003-09-3050 ↗
68. Engineered human nanoferritin bearing the drug genz-644282 for cancer therapy10.3390/pharmaceutics12100992 ↗
69. Anticancer nanocage platforms for combined immunotherapy designed to harness immune checkpoints and deliver anticancer drugs10.1016/j.biomaterials.2021.120685 ↗
70. tLyP-1 peptide functionalized human H chain ferritin for targeted delivery of paclitaxel10.2147/IJN.S289005 ↗
71. Selective targeting of cancer-associated fibroblasts by engineered H-ferritin nanocages loaded with navitoclax10.3390/cells10020328 ↗
72. Fine-tuned H-ferritin nanocage with multiple gold clusters as near infrared kidney specific targeting nanoprobe10.1021/bc5005284 ↗